196 related articles for article (PubMed ID: 19402280)
1. Evaluation of pre transplant T-cell activation status by soluble CD 30 determination.
Abbas K; Muzaffar R; Zafar MN; Mubarak M; Naqvi SA; Rizvi SA
J Pak Med Assoc; 2009 Apr; 59(4):212-5. PubMed ID: 19402280
[TBL] [Abstract][Full Text] [Related]
2. Posttransplant soluble CD30 as a predictor of acute renal allograft rejection.
Kamali K; Abbasi MA; Farokhi B; Abbasi A; Fallah P; Seifee MH; Ghadimi N; Rezaie AR
Exp Clin Transplant; 2009 Dec; 7(4):237-40. PubMed ID: 20353374
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA.
Solgi G; Furst D; Mytilineos J; Pourmand G; Amirzargar AA
Transpl Immunol; 2012 Mar; 26(2-3):81-7. PubMed ID: 22182633
[TBL] [Abstract][Full Text] [Related]
4. Relation between pretransplant serum levels of soluble CD30 and acute rejection during the first 6 months after a kidney transplant.
Shooshtarizadeh T; Mohammadali A; Ossareh S; Ataipour Y
Exp Clin Transplant; 2013 Jun; 11(3):229-33. PubMed ID: 23477385
[TBL] [Abstract][Full Text] [Related]
5. Plasma levels of soluble CD30 in kidney graft recipients as predictors of acute allograft rejection.
Ayed K; Abdallah TB; Bardi R; Abderrahim E; Kheder A
Transplant Proc; 2006 Sep; 38(7):2300-2. PubMed ID: 16980071
[TBL] [Abstract][Full Text] [Related]
6. Soluble CD30 levels in recipients undergoing heart transplantation do not predict post-transplant outcome.
Ypsilantis E; Key T; Bradley JA; Morgan CH; Tsui S; Parameshwar J; Taylor CJ
J Heart Lung Transplant; 2009 Nov; 28(11):1206-10. PubMed ID: 19782609
[TBL] [Abstract][Full Text] [Related]
7. Serial soluble CD30 measurements as a predictor of kidney graft outcome.
Halim MA; Al-Otaibi T; Al-Muzairai I; Mansour M; Tawab KA; Awadain WH; Balaha MA; Said T; Nair P; Nampoory MR
Transplant Proc; 2010 Apr; 42(3):801-3. PubMed ID: 20430176
[TBL] [Abstract][Full Text] [Related]
8. Association of high post-transplant soluble CD30 serum levels with chronic allograft nephropathy.
Grenzi PC; Campos ÉF; Tedesco-Silva H; Felipe CR; Franco MF; Soares MF; Medina-Pestana JO; Gerbase-Delima M
Transpl Immunol; 2013 Dec; 29(1-4):34-8. PubMed ID: 23928467
[TBL] [Abstract][Full Text] [Related]
9. Immunological monitoring after organ transplantation: potential role of soluble CD30 blood level measurement.
Truong DQ; Darwish AA; Gras J; Wieërs G; Cornet A; Robert A; Mourad M; Malaise J; de Ville de Goyet J; Reding R; Latinne D
Transpl Immunol; 2007 Jun; 17(4):283-7. PubMed ID: 17493532
[TBL] [Abstract][Full Text] [Related]
10. High pretransplantation soluble CD30 levels: impact in renal transplantation.
Giannoli C; Bonnet MC; Perrat G; Houillon A; Reydet S; Pouteil-Noble C; Villar E; Lefrançois N; Morelon E; Dubois V
Transplant Proc; 2007 Oct; 39(8):2574-5. PubMed ID: 17954178
[TBL] [Abstract][Full Text] [Related]
11. CD30, a marker to detect the high-risk kidney transplant recipients.
Spiridon C; Nikaein A; Lerman M; Hunt J; Dickerman R; Mack M
Clin Transplant; 2008; 22(6):765-9. PubMed ID: 19040559
[TBL] [Abstract][Full Text] [Related]
12. Pre-transplant soluble CD30 level as a predictor of not only acute rejection and graft loss but pneumonia in renal transplant recipients.
Wang D; Wu WZ; Chen JH; Yang SL; Wang QH; Zeng ZX; Tan JM
Transpl Immunol; 2010 Feb; 22(3-4):115-20. PubMed ID: 20036333
[TBL] [Abstract][Full Text] [Related]
13. Pre-transplant immune state defined by serum markers and alloreactivity predicts acute rejection after living donor kidney transplantation.
Vondran FW; Timrott K; Kollrich S; Steinhoff AK; Kaltenborn A; Schrem H; Klempnauer J; Lehner F; Schwinzer R
Clin Transplant; 2014 Sep; 28(9):968-79. PubMed ID: 24931031
[TBL] [Abstract][Full Text] [Related]
14. Post-transplant monitoring of soluble CD30 level as predictor of graft outcome: a single center experience from China.
Wang D; Wu W; Yang S; Wang Q; Tan J
Transpl Immunol; 2012 Dec; 27(4):146-50. PubMed ID: 23079227
[TBL] [Abstract][Full Text] [Related]
15. Soluble CD30 and ELISA-detected human leukocyte antigen antibodies for the prediction of acute rejection in pediatric renal transplant recipients.
Billing H; Sander A; Süsal C; Ovens J; Feneberg R; Höcker B; Vondrak K; Grenda R; Friman S; Milford DV; Lucan M; Opelz G; Tönshoff B
Transpl Int; 2013 Mar; 26(3):331-8. PubMed ID: 23279372
[TBL] [Abstract][Full Text] [Related]
16. Pretransplant soluble CD30 level has limited effect on acute rejection, but affects graft function in living donor kidney transplantation.
Kim MS; Kim HJ; Kim SI; Ahn HJ; Ju MK; Kim HJ; Jeon KO; Kim YS
Transplantation; 2006 Dec; 82(12):1602-5. PubMed ID: 17198243
[TBL] [Abstract][Full Text] [Related]
17. Soluble CD30 and HLA antibodies as potential risk factors for kidney transplant rejection.
Slavcev A; Lácha J; Honsová E; Sajdlová H; Lodererová A; Vitko S; Skibová J; Striz I
Transpl Immunol; 2005 Jun; 14(2):117-21. PubMed ID: 15935302
[TBL] [Abstract][Full Text] [Related]
18. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
[TBL] [Abstract][Full Text] [Related]
19. Soluble CD30 in renal transplant recipients: is it a good biomarker to predict rejection?
Azarpira N; Aghdaie MH; Malekpour Z
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):31-6. PubMed ID: 20061689
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations.
Cinti P; Pretagostini R; Arpino A; Tamburro ML; Mengasini S; Lattanzi R; De Simone P; Berloco P; Molajoni ER
Transplantation; 2005 May; 79(9):1154-6. PubMed ID: 15880060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
